Palmoplantar Pustulosis Market Report 2025

The palmoplantar pustulosis market size has grown strongly in recent years. It will grow from $1.93 billion in 2024 to $2.1 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth observed during the historical period can be attributed to factors such as the increasing prevalence of autoimmune disorders, greater awareness of rare skin diseases, higher healthcare spending, and the growing adoption of telemedicine in dermatology.

The palmoplantar pustulosis market size is expected to see strong growth in the next few years. It will grow to $2.84 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period is expected to be driven by the rising adoption of biologic therapies, increased investments in dermatology research, a growing pipeline of novel treatments, rising demand for personalized medicine, and the increasing prevalence of chronic skin conditions. Key trends for the forecast period include advancements in dermatology research, a shift toward biologics and immunomodulators, the integration of artificial intelligence in dermatological diagnosis, the development of advanced topical formulations, and the use of machine learning in dermatological research.

The rising prevalence of skin disorders is expected to drive the growth of the palmoplantar pustulosis market. Skin disorders are conditions that impact the skin’s structure, function, or appearance, and their increasing incidence is attributed to environmental changes, lifestyle habits, and genetic factors. Environmental influences, such as air pollution, extreme weather conditions, and exposure to harmful chemicals, can irritate the skin and trigger conditions such as eczema or acne. Palmoplantar pustulosis is a chronic skin disorder that primarily affects the palms of the hands and soles of the feet, causing pustules, redness, and scaling. This condition can be managed with various treatments to improve skin health and reduce discomfort. For example, in 2022, the International Eczema Council reported that approximately 223 million people worldwide were affected by atopic dermatitis, with 43 million of them aged between 1 and 4 years old. As skin disorders become more prevalent, the growth of the palmoplantar pustulosis market is accelerating.

Companies in the palmoplantar pustulosis market are developing innovative treatments, such as monoclonal antibodies targeting inflammatory pathways, to improve patient outcomes. Monoclonal antibodies (mAbs) are identical antibodies produced by a single B cell clone and are designed to target specific antigens for therapeutic or diagnostic purposes. For example, in August 2023, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, received partial approval for LUMICEF for palmoplantar pustulosis treatment in Japan. LUMICEF is a targeted therapy that blocks IL-17, providing rapid and lasting relief for inflammatory conditions such as psoriasis and palmoplantar pustulosis. Its goal is to reduce inflammation and enhance the quality of life for patients with chronic skin diseases.

In October 2024, Organon & Co., a U.S.-based pharmaceutical company, acquired Dermavant Sciences Ltd. for an undisclosed sum. This acquisition allows Organon to strengthen its dermatology portfolio and improve women’s health by offering innovative treatments for chronic skin conditions. Dermavant Sciences, based in the U.S., is focused on developing novel therapies for immuno-dermatological conditions, particularly targeting unmet needs in diseases such as plaque psoriasis and atopic dermatitis.

Major players in the palmoplantar pustulosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis International AG, GlaxoSmithKline PLC (GSK), Amgen Inc., C.H. Boehringer Sohn AG & Co. KG, Bausch Health Companies Inc., Chugai Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Kyowa Kirin Co. Ltd., Swedish Orphan Biovitrum AB (Sobi), Almirall S.A., MorphoSys AG, MoonLake Immunotherapeutics AG, Aristea Therapeutics Inc., AnaptysBio Inc., Taiho Pharmaceutical Co. Ltd., Kamari Pharma Ltd.

North America was the largest region in the palmoplantar pustulosis market in 2024. The regions covered in palmoplantar pustulosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the palmoplantar pustulosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Palmoplantar pustulosis is a chronic skin disorder characterized by the development of pustules (small, pus-filled blisters) on the palms of the hands and soles of the feet. This condition often leads to redness, scaling, and thickening of the skin in these areas. It can be painful and is commonly associated with other skin conditions, such as psoriasis.

The primary treatment options for palmoplantar pustulosis include topical treatments, systemic therapies, biologics, and phototherapy. Topical treatments aim to reduce inflammation, manage symptoms, and prevent flare-ups, and may involve corticosteroids, vitamin D analogs, calcineurin inhibitors, keratolytics, or coal tar. These treatments are used in various healthcare settings, such as hospitals, dermatology clinics, and home care environments, and are distributed through multiple channels, including online pharmacies, retail pharmacies, and hospitals.

The palmoplantar pustulosis market research report is one of a series of new reports that provides palmoplantar pustulosis market statistics, including the palmoplantar pustulosis industry global market size, regional shares, competitors with the palmoplantar pustulosis market share, detailed palmoplantar pustulosis market segments, market trends, and opportunities, and any further data you may need to thrive in the palmoplantar pustulosis industry. This palmoplantar pustulosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The palmoplantar pustulosis market consists of revenues earned by entities by providing services such as personalized skincare and counseling, phototherapy services, pharmacological treatment services, and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The palmoplantar pustulosis market also includes sales of phototherapy devices, oral systemic therapies, medicated skincare products, topical corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.